Stocktoria
STAAR SURGICAL CO STAA
STAAR SURGICAL CO (STAA) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2026 revenue was $239.4M at a -33.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.31 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.538 |
| Retained earnings / assets | -0.328 |
| EBIT / assets | -0.203 |
| Equity / liabilities | 3.202 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| STAA | STAAR SURGICAL CO | 1/9 | 4.46 | — | -23.7% |
| RXST | RxSight, Inc. | 2/9 | 5.56 | — | -3.9% |
| LUCY | Innovative Eyewear Inc | 4/9 | — | — | — |
| WRBY | Warby Parker Inc. | 5/9 | -0.22 | — | +13% |
| EYE | National Vision Holdings, Inc. | 7/9 | 0.82 | 51 | +9% |
| COO | COOPER COMPANIES, INC. | 6/9 | 4.99 | 36.9 | +5.1% |
| BLCO | Bausch & Lomb Corp | 3/9 | 1.24 | — | +6.5% |
About STAAR SURGICAL CO
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
FAQ
Is STAA financially healthy?
STAAR SURGICAL CO's Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does STAA pay a dividend?
No, STAAR SURGICAL CO does not currently pay a dividend.
How profitable is STAA?
In FY2026, STAAR SURGICAL CO had a net margin of -33.6% and a return on equity of -23.4%.
Is STAA overvalued or undervalued?
STAAR SURGICAL CO trades at about 59.1× trailing earnings — below its 10-year norm (10-year range 65.1×–1642.0×, median 272.3×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for STAA?
The average Wall-Street price target for STAAR SURGICAL CO is $29.67, about 16.8% above the recent price, from 9 analysts.
Is STAA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on STAAR SURGICAL CO: a Piotroski F-score of 1/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2026-01-02. Facts plus Stocktoria's own computed scores — not investment advice.